- Home
- CATX
as 07-26-2024 4:00pm EST
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 870.3M | IPO Year: | N/A |
| Target Price: | $22.40 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.10 - $19.10 | Next Earning Date: | 08-15-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -62.73% | Revenue Growth (next year): | -38.66% |
Stock Insider Trading Activity of Perspective Therapeutics Inc. (CATX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hunt Jonathan Robert | CATX | Chief Financial Officer | Jun 17 '24 | Buy | $9.82 | 1,800 | $17,667.00 | 35,971 | SEC Form 4 |
| Woods Lori A | CATX | Director | Jun 14 '24 | Buy | $10.90 | 4,504 | $49,093.60 | 159,902 | SEC Form 4 |
| Woods Lori A | CATX | Director | Jun 14 '24 | Buy | $10.80 | 83 | $896.40 | 159,985 | SEC Form 4 |
| Spoor Johan M. | CATX | CEO | Jun 13 '24 | Buy | $1.17 | 100,000 | $117,430.00 | 137,572 | SEC Form 4 |
| Woods Lori A | CATX | Director | Jun 3 '24 | Buy | $1.46 | 34,246 | $49,992.31 | 1,553,984 | SEC Form 4 |
| Hunt Jonathan Robert | CATX | Chief Financial Officer | May 31 '24 | Buy | $1.40 | 13,006 | $18,207.10 | 329,716 | SEC Form 4 |
| Hunt Jonathan Robert | CATX | Chief Financial Officer | May 31 '24 | Buy | $1.40 | 12,000 | $16,800.00 | 341,716 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | May 31 '24 | Buy | $1.38 | 55,000 | $75,900.00 | 423,792 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | May 29 '24 | Buy | $1.32 | 11,375 | $15,015.00 | 350,136 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | May 29 '24 | Buy | $1.34 | 18,656 | $24,999.04 | 368,792 | SEC Form 4 |
| Lantheus Alpha Therapy, LLC | CATX | 10% Owner | Mar 6 '24 | Buy | $0.95 | 60,431,039 | $57,409,487.05 | 116,773,394 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 30 '24 | Buy | $0.71 | 18,579 | $13,191.09 | 230,134 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 30 '24 | Buy | $0.71 | 5,127 | $3,640.17 | 235,261 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 30 '24 | Buy | $0.71 | 57,121 | $40,555.91 | 292,382 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 30 '24 | Buy | $0.72 | 42,879 | $30,872.88 | 335,261 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 30 '24 | Buy | $0.70 | 3,500 | $2,450.00 | 338,761 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 26 '24 | Buy | $0.61 | 12,250 | $7,472.50 | 87,926 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 26 '24 | Buy | $0.61 | 14,850 | $9,058.50 | 102,776 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 26 '24 | Buy | $0.59 | 8,513 | $5,022.67 | 111,289 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 26 '24 | Buy | $0.55 | 25,000 | $13,750.00 | 136,289 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 26 '24 | Buy | $0.54 | 50,000 | $27,000.00 | 186,289 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 26 '24 | Buy | $0.64 | 4,031 | $2,579.84 | 190,320 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 26 '24 | Buy | $0.64 | 21,235 | $13,590.40 | 211,555 | SEC Form 4 |
| Puhlmann Markus | CATX | Chief Medical Officer | Jan 24 '24 | Buy | $0.50 | 280,000 | $139,888.00 | 1,375,425 | SEC Form 4 |
| Williamson Robert F III | CATX | Director | Jan 24 '24 | Buy | $0.49 | 29,862 | $14,632.38 | 53,542 | SEC Form 4 |
Latest Perspective Therapeutics Inc. News
CATX Breaking Stock News: Dive into CATX Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
BofA Securities Starts Perspective Therapeutics With Buy Rating, $24 Price Target
GlobeNewswire
5 days ago
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results
Zacks
10 days ago
Wall Street Analysts Think Perspective Therapeutics (CATX) Could Surge 80.31%: Read This Before Placing a Bet
MT Newswires
a month ago
Sector Update: Health Care Stocks Softer Wednesday Afternoon
MT Newswires
a month ago
Perspective Therapeutics to Join Russell 3000 Index on July 1
GlobeNewswire
a month ago
Perspective Therapeutics Announces Inclusion in the Russell 3000® Index
MT Newswires
2 months ago
Perspective Therapeutics to Reverse Split Common Shares
GlobeNewswire
2 months ago
Perspective Therapeutics Announces 1-for-10 Reverse Stock Split
Compare CATX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CATX Perspective Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.